Product
RG002
Aliases
RG002 injection
1 clinical trial
4 indications
Indication
HPV Type 16 InfectionIndication
Human Papillomavirus Type 18 InfectionClinical trial
An Open-Label, Phase 1/2 Study to Evaluate the Safety, Tolerability, Immunogenicity and Efficacy of RG002 Injection (an mRNA Therapeutic Vaccine) in Subjects With Human Papillomavirus (HPV) 16 or 18 Associated Cervical Intraepithelial Neoplasia Grade 2 or 3 (CIN2/3)Status: Not yet recruiting, Estimated PCD: 2026-10-01